HIV/AIDS Drug Mechanism
Efavirenz enhances HIV-1 RT p66/p66 and p51/p51 homodimer interactions
Published in AIDS Weekly, April 11th, 2005
"The nonnucleoside reverse transcriptase inhibitor, efavirenz (EFV), is a potent enhancer of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) p66/p51 heterodimerization.
"While the mechanism of RT heterodimer formation in HIV-1 infected cells is not completely understood, it has been speculated that Gag-Pol/Gag-Pol and/or RT homodimer interactions may represent important intermediates in the pathway," scientists writing in the journal FEBS Letters report.
"To elucidate whether EFV impacts on these interactions," said G. Tachedjian...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-04-11)
More Articles from AIDS Weekly
- HIV/AIDS Drug Development
Tuftsin-AZT inhibits HIV RT and augments host immunogenic cell function - HIV/AIDS Epidemiology
Low CCR5Delta32 frequency related to higher susceptibility to HIV-1 infection - HIV/AIDS Lipodystrophy
Metabolic and body composition changes vary according to HAART choice - HIV/AIDS Pathogenesis
HIV-1 Vpr inhibits maturation and activation of macrophages and dendritic cells - Arrhythmia
HIV protease inhibitors may predispose patients to cardiac arrhythmias - Avian Influenza
Animal health company launches new Avian Influenza vaccine - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
